Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 220.85B |
| Revenue (ttm) | 44.95B |
| Net Income (ttm) | 11.48B |
| Shares Out | 1.92B |
| EPS (ttm) | 5.82 |
| PE Ratio | 19.78 |
| Forward PE | 16.60 |
| Dividend | 3.50 (3.06%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 2,504,082 |
| Average Volume | 3,128,404 |
| Open | 114.00 |
| Previous Close | 114.34 |
| Day's Range | 113.96 - 115.50 |
| 52-Week Range | 81.10 - 116.78 |
| Beta | 0.45 |
| RSI | 65.85 |
| Earnings Date | Feb 4, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
Novartis CEO on impact of 'most favored nation' drug pricing
Novartis CEO Vas Narasimham, speaking with CNBC about lowering drug prices, said the focus should be on reducing patient out-of-pocket drug costs, not list or net prices, though believes progress is m...
Healthcare debate should focus on out-of-pocket costs, not list prices – Novartis CEO
Novartis CEO Vas Narasimhan: ‘We really should be talking about out-of-pocket costs' in the U.S.
Vas Narasimhan, CEO of Novartis, joins 'Money Movers' to discuss U.S. drug pricing, healthcare, and more.
Novartis CEO Vas Narasimhan: ‘We really should be talking about out-of-pocket costs’ in the U.S.
Vas Narasimhan, CEO of Novartis, joins 'Money Movers' to discuss U.S. drug pricing, healthcare, and more.
Engaging In Insider Activity, Patrick Mayes At Incyte Exercises Options Worth $0
A large exercise of company stock options by Patrick Mayes , EVP & Chief Scientific Officer at Incyte (NASDAQ: INCY) was disclosed in a new SEC filing on January 21, as part of an insider exercise. W...
Thomas Tray Decides To Exercise Options At Incyte Worth $0
A large exercise of company stock options by Thomas Tray , Principal Accounting Officer at Incyte (NASDAQ: INCY) was disclosed in a new SEC filing on January 21, as part of an insider exercise. What ...
Engaging In Insider Activity, Matteo Trotta At Incyte Exercises Options Worth $0
In a new SEC filing on January 21, it was revealed that Trotta, EVP at Incyte (NASDAQ: INCY), executed a significant exercise of company stock options. What Happened: Disclosed in a Form 4 filing on ...
Insider Decision Unfolding At Incyte: Khairie Mohamed Issa Exercises Options, Resulting In $0
In a new SEC filing on January 21, it was revealed that Issa, EVP at Incyte (NASDAQ: INCY), executed a significant exercise of company stock options. What Happened: Issa, EVP at Incyte, exercised sto...
Steven Stein Decides To Exercise Options At Incyte Worth $0
A large exercise of company stock options by Steven Stein , EVP & Chief Medical Officer at Incyte (NASDAQ: INCY) was disclosed in a new SEC filing on January 21, as part of an insider exercise. What ...
Breaking Update: PABLO CAGNONI Engages In Options Exercise At Incyte Realizing $0
A substantial insider activity was disclosed on January 21, as CAGNONI, President at Incyte (NASDAQ: INCY), reported the exercise of a large sell of company stock options. What Happened: CAGNONI, Pre...
Canton Hathaway, LLC Sells 159 Shares of Novartis AG (NVS)
Canton Hathaway, LLC Sells 159 Shares of Novartis AG (NVS)
Independence Bank of Kentucky Buys 78 Shares of Novartis AG (NVS)
Independence Bank of Kentucky Buys 78 Shares of Novartis AG (NVS)
BXM Wealth LLC Buys 37,639 Shares of Novartis AG (NVS)
BXM Wealth LLC Buys 37,639 Shares of Novartis AG (NVS)
Novartis CEO: Confident we are shielded from any further U.S. tariffs
Novartis CEO Vas Narasimhan told CNBC in Davos that he believes the Swiss drugmaker is protected from any additional U.S. tariffs on Europe, citing its U.S. manufacturing footprint, inventory levels, ...
Blue Square Asset Management, LLC Sells 427 Shares of Novartis AG (NVS)
Blue Square Asset Management, LLC Sells 427 Shares of Novartis AG (NVS)
Novartis (NVS) CEO Confident in U.S. Tariff Protection Due to Major Investment
Novartis (NVS) CEO Confident in U.S. Tariff Protection Due to Major Investment
Novartis could have a U.S. deal that shields it from tariffs, CEO tells CNBC
The continent's pharma sector could be one of its worst hit by Trump's latest tariffs on some European countries.
Novartis expects to eliminate US tariff exposure by mid‑2026, CEO tells CNBC
Novartis CEO Vas Narasimhan told CNBC on Tuesday he expects the drugmaker's agreement with the U.S. government and its expanding manufacturing footprint in the country to protect it from potential tar...
Novartis CEO: Confident we are shielded from any further U.S. tariffs
Novartis CEO Vas Narasimhan told CNBC in Davos that he believes the Swiss drugmaker is protected from any additional U.S. tariffs on Europe, citing its U.S. manufacturing footprint, inventory levels, ...
International Vector Equity Portfolio Sells 12,054 Shares of Novartis AG (NVS)
International Vector Equity Portfolio Sells 12,054 Shares of Novartis AG (NVS)
Oregon Pacific Wealth Management, LLC Sells 51 Shares of Novartis AG (NVS)
Oregon Pacific Wealth Management, LLC Sells 51 Shares of Novartis AG (NVS)
Heck Capital Advisors, LLC Buys 30 Shares of Novartis AG (NVS)
Heck Capital Advisors, LLC Buys 30 Shares of Novartis AG (NVS)
LARGE CAP INTERNATIONAL PORTFOLIO Sells 21,850 Shares of Novartis AG (NVS)
LARGE CAP INTERNATIONAL PORTFOLIO Sells 21,850 Shares of Novartis AG (NVS)
International Vector Equity Portfolio Sells 5 Shares of Novartis AG (NVS)
International Vector Equity Portfolio Sells 5 Shares of Novartis AG (NVS)
FDA Grants Novartis Breakthrough Therapy Status To Ianalumab For Sjögren's Disease
(RTTNews) - Novartis announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ianalumab for Sjögren's disease, the second most prevalent rheumatic autoimmun...